

Attorney Docket No.: 10004.204-US



PATENT

0590
11/3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No: To be assigned

Serial No.: 09/925,576

Group Art Unit: To be assigned

Filed: August 9, 2001

Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on August 28, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 10004.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No: To be assigned

Serial No.: 09/925,576

Group Art Unit: To be assigned

Filed: August 9, 2001

Examiner: To be assigned

For: Amylase Variants

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. WO 99/19467
2. WO 96/23874
3. WO 97/41213


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or

before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: August 28, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.